Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical and supplements company focused on developing and marketing disruptive sublingual delivery technology for known drugs and nutraceuticals. The company’s product pipeline includes a high-dose sublingual aspirin formulation, melatonin sleep-aid products, vitamins D, E and K, an erectile dysfunction medication, caffeine-based supplements, and anti-nausea agents such as meclizine and ondansetron. Aspire utilizes its patent-pending sublingual absorption platform to bypass the gastrointestinal tract, enabling rapid drug uptake and potentially improved therapeutic outcomes.

Aspire Biopharma Holdings, Inc. expects to generate revenue primarily through the sale of its products once they receive regulatory approval, beginning with its caffeine supplement sold under the Buzz Bomb brand through its wholly owned subsidiary Buzz Bomb Caffeine Company LC. Additionally, the company anticipates revenue from licensing or collaboration agreements that could provide upfront payments, milestone payments, and royalties, although no such agreements are currently in place. Revenue may also derive from future sales of approved drug candidates such as the high-dose sublingual aspirin for myocardial infarction prevention.

Aspire Biopharma Holdings, Inc. occupies a niche position within the biopharmaceutical and supplements industry by leveraging a novel sublingual delivery mechanism that differentiates its candidates from traditional oral formulations. The company claims competitive advantages including faster bioavailability, reduced gastrointestinal irritation, and the ability to deliver high doses without metabolic dilution. It faces competition from large pharmaceutical firms such as Bayer, Pfizer, and Johnson & Johnson for its aspirin candidate, as well as established supplement and over-the-counter brands for its melatonin, vitamin, and caffeine products. To date, no sublingual aspirin product is approved or listed in the FDA’s Orange Book, giving Aspire a potential first-mover advantage if approval is obtained.

The company’s customer base includes hospitals and specialty care providers for its prescription aspirin product, retail consumers for over-the-counter melatonin, vitamins, and caffeine supplements, and fitness enthusiasts reached through convention sales and online channels. Aspire has sold initial versions of its Buzz Bomb caffeine product at fitness conventions and began broader distribution in the third quarter of 2025. Specific customer names are not disclosed in the filing.